Sample Size Benefits of Replicate Design with ABE [Power / Sample Size]

posted by Sereng  – USA, 2023-05-24 17:41 (131 d 02:01 ago) – Posting: # 23566
Views: 783

Folks, I have three questions:

(1) If you conduct a full replicate crossover design BE study (T x 2, R x 2, e.g., TRTR|RTRT) is there any sample size efficiency (fewer patients required) with ABE analysis or is it no different (in terms of sample size) than a non-replicate crossover design BE study (T x1, R x 1) with ABE analysis.

(2) For demonstrably HVD (WSV >30%), why do some product specific guidance for ANDA suggest (or allow) full replicate designs and others do not mention this approach?

(3) For demonstrably HVD (WSV >30%), why do some Clinical Divisions object to use of full replicate design studies in 505(b)(2) NDAs?

Any input would be appreciated!

Biostatistically Challenged CEO

Complete thread:

UA Flag
 Admin contact
22,764 posts in 4,776 threads, 1,628 registered users;
18 visitors (0 registered, 18 guests [including 5 identified bots]).
Forum time: 19:43 CEST (Europe/Vienna)

The object of statistics is information.
The objective of statistics is the understanding of information
contained in data.    Irwin and Marylees Miller

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz